William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today.
Sami Corwin has given his Buy rating due to a combination of factors influencing Sarepta Therapeutics’ current and future performance. Despite the revenue miss in the first quarter, with total product revenue reaching $611.5 million against the expected $672.5 million, the company still demonstrated a significant year-over-year growth of 70%. This indicates a strong underlying business model and potential for recovery and growth.
Sami Corwin also considered the revised guidance for 2025, which reflects the company’s proactive approach to addressing operational challenges, such as the extended turnaround times for Elevidys treatments. The management’s commitment to ensuring patient safety through rigorous screening protocols, despite causing delays, showcases a focus on long-term sustainability. Additionally, the positive interactions with the FDA amidst leadership changes further reinforce confidence in the company’s regulatory strategy and potential for future approvals.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $113.00 price target.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year.